BioLineRx Ltd. (BLRX)Healthcare | Biotechnology | Hevel Modi'in, Israel | NasdaqCM
2.17 USD
|
Hot Take ↕ | Oct. 10, 2026, 1:11 a.m. EDT
The investment case here is severely compromised by a decade-long structural decline. Despite the company reporting preclinical synergy in ovarian cancer models—a positive scientific development—the market has punished the stock relentlessly, erasing over 99% of its value since 2016. The most recent annual performance shows another significant drop, confirming a multi-year trend of deterioration that outweighs any single positive news item. Fundamentally, the business is bleeding cash with negative operating margins and no revenue growth, while the balance sheet remains fragile. The options market reflects this despair, with traders placing heavy hedges at the $5 strike level, effectively betting that the stock will struggle to recover even to that threshold. While the biotech pipeline offers theoretical potential, the current financial reality and the relentless downward price trajectory make this a dangerous speculative vehicle rather than a viable investment. |
| Model | MAE |
|---|---|
| AutoTheta ✓ | 0.033496 |
| MSTL | 0.058889 |
| AutoETS | 0.062840 |
| AutoARIMA | 0.062840 |
Forecast horizon: 45 days | Selected: AutoTheta
| Forecast Reliability | |
|---|---|
| Score | 47% |
| H-stat | 5.39 |
| Ljung-Box p | 0.000 |
| Jarque-Bera p | 0.366 |
| Excess Kurtosis | 0.29 |
| Attribute | Value |
|---|---|
| Sector | Healthcare |
| Debt to Equity Ratio | 47.783 |
| Revenue per Share | 0.6 |
| Market Cap | 10,802,729 |
| Forward P/E | -0.86 |
| Beta | 0.70 |
| Website | https://www.biolinerx.com |
As of Oct. 10, 2026, 1:11 a.m. EDT: Speculators are overwhelmingly positioning for downside protection rather than upside. Put open interest is concentrated deep in-the-money at the $5 strike, acting as a floor against further collapse. Call activity is sparse and entirely out-of-the-money, with heavy open interest at $5 and $7.50 strikes suggesting bets on a recovery to those levels, but the lack of volume and the dominance of put positioning indicate a bearish sentiment where traders are hedging against further losses rather than anticipating a rally.
| Attribute | Value |
|---|---|
| 52 Week Change | -0.460199 |
| Address1 | Modi’in Technology Park |
| Address2 | 2 HaMa’ayan Street |
| All Time High | 4,122.0 |
| All Time Low | 2.14 |
| Ask | 2.31 |
| Ask Size | 1 |
| Average Daily Volume10 Day | 18,710 |
| Average Daily Volume3 Month | 16,668 |
| Average Volume | 16,668 |
| Average Volume10Days | 18,710 |
| Beta | 0.702 |
| Bid | 2.2 |
| Bid Size | 1 |
| Book Value | 3.0 |
| City | Hevel Modi'in |
| Compensation As Of Epoch Date | 1,767,139,200 |
| Country | Israel |
| Crypto Tradeable | 0 |
| Currency | USD |
| Current Price | 2.17 |
| Current Ratio | 1.195 |
| Custom Price Alert Confidence | HIGH |
| Date Short Interest | 1,790,726,400 |
| Day High | 2.27 |
| Day Low | 2.11 |
| Debt To Equity | 47.783 |
| Display Name | BioLineRx |
| Dividend Date | 1,563,148,800 |
| Dividend Yield | 0.0 |
| Earnings Call Timestamp End | 1,788,179,400 |
| Earnings Call Timestamp Start | 1,788,179,400 |
| Earnings Timestamp | 1,788,179,400 |
| Earnings Timestamp End | 1,795,437,000 |
| Earnings Timestamp Start | 1,795,437,000 |
| Ebitda | -12,118,000 |
| Ebitda Margins | 0.0 |
| Enterprise To Ebitda | -0.593 |
| Enterprise To Revenue | 5.166 |
| Enterprise Value | 7,191,201 |
| Eps Current Year | -3.14 |
| Eps Forward | -2.52 |
| Eps Trailing Twelve Months | 0.0 |
| Esg Populated | 0 |
| Exchange | NCM |
| Exchange Data Delayed By | 15 |
| Exchange Timezone Name | America/New_York |
| Exchange Timezone Short Name | EDT |
| Fax | 972 8 642 9101 |
| Fifty Day Average | 2.588 |
| Fifty Day Average Change | -0.41799998 |
| Fifty Day Average Change Percent | -0.16151467 |
| Fifty Two Week Change Percent | -46.0199 |
| Fifty Two Week High | 4.09 |
| Fifty Two Week High Change | -1.9200001 |
| Fifty Two Week High Change Percent | -0.46943766 |
| Fifty Two Week Low | 2.11 |
| Fifty Two Week Low Change | 0.06000018 |
| Fifty Two Week Low Change Percent | 0.028436106 |
| Fifty Two Week Range | 2.11 - 4.09 |
| Financial Currency | USD |
| First Trade Date Milliseconds | 1,311,773,400,000 |
| Float Shares | 4,138,654 |
| Forward Eps | -2.52 |
| Forward P E | -0.86111116 |
| Free Cashflow | -8,852,375 |
| Full Exchange Name | NasdaqCM |
| Full Time Employees | 20 |
| Fullday Change | 0.0 |
| Fullday Change Percent | 0.0 |
| Fullday Price | 2.17 |
| Gmt Off Set Milliseconds | -14,400,000 |
| Gross Margins | 0.80029 |
| Gross Profits | 1,114,000 |
| Has Pre Post Market Data | 1 |
| Held Percent Insiders | 0.0343 |
| Held Percent Institutions | 0.01337 |
| Implied Shares Outstanding | 4,978,216 |
| Industry | Biotechnology |
| Industry Disp | Biotechnology |
| Industry Key | biotechnology |
| Is Earnings Date Estimate | 1 |
| Language | en-US |
| Last Fiscal Year End | 1,767,139,200 |
| Last Split Date | 1,738,195,200 |
| Last Split Factor | 1:40 |
| Long Business Summary | BioLineRx Ltd., a biopharmaceutical company, develops and commercializes therapeutics for oncology and rare diseases. The company's pipeline includes GLIX1, an oral, small molecule targeting DNA damage response in glioblastoma and other cancers; and APHEXDA (motixafortide), a peptide that is in Phase 1 clinical trial for the treatment of sickle cell disease, and Phase 2b clinical trial for the treatment of pancreatic cancer, as well as completed Phase 3 clinical trial for the treatment of multiple myeloma. It develops BL-5010, a pen-like applicator containing an acidic aqueous solution for the non-surgical removal of skin lesions. BioLineRx Ltd. was incorporated in 2003 and is headquartered in Hevel Modi'in, Israel. |
| Long Name | BioLineRx Ltd. |
| Market | us_market |
| Market Cap | 10,802,729 |
| Market State | POST |
| Max Age | 86,400 |
| Message Board Id | finmb_5015080 |
| Most Recent Quarter | 1,782,777,600 |
| Net Income To Common | -6,989,000 |
| Next Fiscal Year End | 1,798,675,200 |
| Non Diluted Market Cap | 12,541,991 |
| Number Of Analyst Opinions | 2 |
| Open | 2.27 |
| Operating Cashflow | -10,803,000 |
| Operating Margins | -12.15306 |
| Payout Ratio | 0.0 |
| Phone | 972 8 642 9100 |
| Previous Close | 2.17 |
| Price Eps Current Year | -0.6910828 |
| Price Hint | 4 |
| Price To Book | 0.72333336 |
| Price To Sales Trailing12 Months | 7.760581 |
| Profit Margins | 0.0 |
| Quick Ratio | 1.009 |
| Quote Source Name | Delayed Quote |
| Quote Type | EQUITY |
| Recommendation Key | none |
| Region | US |
| Regular Market Change | 0.0 |
| Regular Market Change Percent | 0.0 |
| Regular Market Day High | 2.27 |
| Regular Market Day Low | 2.11 |
| Regular Market Day Range | 2.11 - 2.27 |
| Regular Market Open | 2.27 |
| Regular Market Previous Close | 2.17 |
| Regular Market Price | 2.17 |
| Regular Market Time | 1,791,921,600 |
| Regular Market Volume | 11,800 |
| Return On Assets | -0.19822 |
| Return On Equity | -0.55272 |
| Revenue Growth | -0.033 |
| Revenue Per Share | 0.6 |
| Sand P52 Week Change | 0.17502642 |
| Sector | Healthcare |
| Sector Disp | Healthcare |
| Sector Key | healthcare |
| Shares Outstanding | 4,978,216 |
| Shares Percent Shares Out | 0.0292 |
| Shares Short | 145,570 |
| Shares Short Previous Month Date | 1,788,134,400 |
| Shares Short Prior Month | 135,948 |
| Short Name | BioLineRx Ltd. |
| Short Percent Of Float | 0.0293 |
| Short Ratio | 5.3 |
| Source Interval | 15 |
| Symbol | BLRX |
| Target High Price | 26.0 |
| Target Low Price | 18.0 |
| Target Mean Price | 22.0 |
| Target Median Price | 22.0 |
| Total Cash | 13,078,000 |
| Total Cash Per Share | 2.994 |
| Total Debt | 7,941,000 |
| Total Revenue | 1,392,000 |
| Tradeable | 0 |
| Trailing Annual Dividend Rate | 0.0 |
| Trailing Annual Dividend Yield | 0.0 |
| Trailing Eps | 0.0 |
| Trailing Peg Ratio | None |
| Triggerable | 1 |
| Two Hundred Day Average | 2.7984 |
| Two Hundred Day Average Change | -0.62839985 |
| Two Hundred Day Average Change Percent | -0.22455685 |
| Type Disp | Equity |
| Volume | 11,800 |
| Website | https://www.biolinerx.com |
| Zip | 7,177,871 |